Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06342310 · ClinicalTrials.gov registry record · Phase 2
RE104 Safety and Efficacy Study in Postpartum Depression
A Phase 2 study, sponsored by Reunion Neuroscience.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT06342310 is a Phase 2 study that has completed, run by Reunion Neuroscience. The registered enrollment target is 84 participants.
The verdict
NCT06342310, a Phase 2 study, has completed, sponsored by Reunion Neuroscience.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-control.
Interventions
- DRUG RE104 for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2024-06-14 |
| Est. Completion | 2025-06-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06342310
The ClinicalTrials.gov registry entry for NCT06342310 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Reunion Neuroscience, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RE104 for Injection is the first listed.
NCT06342310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06342310 about?
NCT06342310 is a clinical study titled "RE104 Safety and Efficacy Study in Postpartum Depression". The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-control.
What is the current status of trial NCT06342310?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2024-06-14. Estimated completion is 2025-06-16.
What interventions are being tested in trial NCT06342310?
The interventions under investigation include: RE104 for Injection (DRUG).
Who is sponsoring clinical trial NCT06342310?
This trial is sponsored by Reunion Neuroscience, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.